Danaher Corporation (DHR)
| Market Cap | 150.37B |
| Revenue (ttm) | 23.88B |
| Net Income (ttm) | 3.90B |
| Shares Out | 714.71M |
| EPS (ttm) | 5.29 |
| PE Ratio | 39.77 |
| Forward PE | 27.47 |
| Dividend | $1.28 (0.61%) |
| Ex-Dividend Date | Mar 28, 2025 |
| Volume | 1,708,335 |
| Open | 211.39 |
| Previous Close | 212.40 |
| Day's Range | 208.59 - 213.77 |
| 52-Week Range | 196.80 - 281.70 |
| Beta | 0.85 |
| Analysts | Buy |
| Price Target | 276.06 (+31.21%) |
| Earnings Date | Apr 22, 2025 |
About DHR
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. It operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment offers bioprocessing technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manuf... [Read more]
Financial Performance
In 2024, Danaher's revenue was $23.88 billion, a decrease of -0.06% compared to the previous year's $23.89 billion. Earnings were $3.90 billion, a decrease of -17.79%.
Financial StatementsAnalyst Forecast
According to 18 analysts, the average rating for DHR stock is "Buy." The 12-month stock price forecast is $276.06, which is an increase of 31.21% from the latest price.
News
8 Upcoming Dividend Increases, Including A King
Highlighting eight companies with upcoming dividend increases, four exceeding 10%, and an average increase of 11.4%, median at 9%. My investment strategy focuses on buying, holding, and expanding stak...
Danaher: Near 5-Year Low Is A Great Entry Point
Danaher Corporation is trading near its 5-year low, presenting a potential buying opportunity for growth investors despite near-term headwinds. DHR's strong fundamentals include leadership in biotechn...
Danaher Schedules First Quarter 2025 Earnings Conference Call
WASHINGTON , March 20, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the first quarter 2025 on Tuesday, April 22, 2025 ...
Beckman Coulter Announces FDA clearance of DxC 500i Clinical Analyzer, an integrated Clinical Chemistry and Immunoassay System
The new DxC 500i Analyzer Offers Flexibility and Scalability with Broad Chemistry and Immunoassay Assay Menu BREA, Calif. , March 10, 2025 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical diagn...
Danaher Corporation (DHR) TD Cowen 45th Annual Health Care Conference Transcript
Danaher Corporation (NYSE:DHR) TD Cowen 45th Annual Health Care Conference Call March 5, 2025 10:30 AM ET Company Participants Rainer Blair – President and Chief Executive Officer Conference Call Par...
Danaher to Present at TD Cowen Health Care Conference
WASHINGTON , Feb. 25, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the TD Cowen Healthcare Conferen...
Industrial Laser Marking Machine Market To Reach USD 6.41 Billion by 2032, Growing at CAGR 8.1% | Coherent, Inc., Danaher Corporation, Epilog Laser
An industrial laser marking machine uses laser technology to engrave, etch, or mark materials with precision for identification, branding, or tracking. An industrial laser marking machine uses laser t...
Danaher Announces Appointment of Charles Lamanna to Danaher Board
WASHINGTON , Feb. 20, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that it has appointed Charles Lamanna to its Board of Directors and to the Board's Science & Technology Commi...
Danaher Increases Quarterly Dividend
WASHINGTON , Feb. 20, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.32 per share of its common s...
Danaher: Self-Inflicted Pessimism?
Danaher Corp. has faced market punishment recently, but maintains strong margins and impressive FCF despite a tough year, indicating resilience and potential for future growth. The company's strategic...
All-In: The 23-Stock Six-Figure Dividend Portfolio I'm Betting My Future On
Thank you to the Seeking Alpha community for your support! Reaching 40,000 followers is a dream come true. Your feedback fuels my work. I've invested 91% of my net worth in 23 high-conviction dividend...
3 Top Value Stocks to Buy and Hold for 2025
These high-quality companies are solid—and their stocks look cheap.
Where I'd Put $10,000 Right Now - My Best Dividend Picks For Income And Growth
I started investing with a modest $4,000, now growing it into a 23-stock portfolio. The median net worth varies by age, but most can invest $10,000 for growth. The goal here isn't to push random picks...
Danaher Analysts Cut Their Forecasts After Downbeat Earnings
Danaher Corporation DHR reported weaker-than-expected fourth-quarter earnings on Wednesday.
Danaher Corporation (DHR) Q4 2024 Earnings Call Transcript
Danaher Corporation (DHR) Q4 2024 Earnings Call Transcript
Danaher misses quarterly profit estimates on weak biotech demand
Danaher on Wednesday missed Wall Street estimates for fourth-quarter profit due to soft demand for tools and services used in drug development by its biotech and pharmaceutical clients.
Danaher Reports Fourth Quarter and Full Year 2024 Results
WASHINGTON , Jan. 29, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the fourth quarter and full year 2024. All results in this release reflect only ...
3 Top Blue-Chip Stocks to Buy and Hold for 2025
#Morningstar #BestStockstoBuyNow #BlueChipStocks The undervalued stocks of these reliable large companies look attractive today. 00:00 Introduction 00:43 Microsoft MSFT 01:29 Pepsi PEP 02:16 Danaher D...
Aldevron Unveils Next-Generation Alchemy™ Cell-Free DNA Technology for Research Grade Applications
FARGO, N.D.--(BUSINESS WIRE)--Aldevron Unveils Next-Generation Alchemy™ Cell-Free DNA Technology for Research Grade Applications.
Danaher: Transition Year Recap
Danaher faced a disappointing 2024, despite beating Q3 expectations, due to unaltered full-year guidance and a significant asset writedown. The company executed a $4.5 billion share buyback, with an a...
The Near-Perfect Dividend Portfolio With 10 Sleep-Well-At-Night Gems
In a challenging market marked by uncertainty, building a resilient portfolio is key to long-term financial stability and peace of mind. Sleep-well-at-night, or SWAN, stocks are key. These reliable di...
Beckman Coulter Introduces Cutting-Edge Research Use Only Assays for Neurodegenerative Disease Research
New, Fully Automated, High-Throughput RUO Assays offered on Beckman Coulter Immunoassay Analyzers BREA, Calif. , Jan. 15, 2025 /PRNewswire/ -- Beckman Coulter Diagnostics, a global leader in advanced ...
Danaher Corporation (DHR) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)
Danaher Corporation (NYSE:DHR) 43rd Annual J.P. Morgan Healthcare Conference January 14, 2024 2:15 PM ET Company Participants Rainer Blair - President and Chief Executive Officer Conference Call Part...
Danaher CEO to Comment on Financial Performance
WASHINGTON , Jan. 13, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") announced that its President and Chief Executive Officer, Rainer M. Blair, will comment tomorrow on the Compa...
Using SA's Stock Screener: Sell 6 Overvalued Blue Chips, With Stagnating Growth
Seeking Alpha's Quant Valuation and Growth Grades identify 6 blue-chip stocks with extremely high valuations matched against limited operating growth potential. Costco, Cencora, West Pharmaceutical Se...